Published in Thorac Cancer on March 30, 2017
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer (2009) 77.71
The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 24.94
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med (2015) 12.54
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med (2015) 11.98
Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med (2015) 10.12
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med (2016) 6.84
Do we need a different set of response assessment criteria for tumor immunotherapy? Clin Cancer Res (2009) 3.01
Pseudoprogression and Immune-Related Response in Solid Tumors. J Clin Oncol (2015) 2.38
Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. J Clin Oncol (2016) 1.70
Pulmonary sarcoid-like granulomatosis induced by ipilimumab. J Clin Oncol (2012) 1.06
Nivolumab-induced organizing pneumonia in a melanoma patient. Jpn J Clin Oncol (2016) 0.98
PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course. Clin Cancer Res (2016) 0.94
High incidence of interstitial lung disease following practical use of osimertinib in patients who had undergone immediate prior nivolumab therapy. Ann Oncol (2017) 0.88
Strategies for combining immunotherapy with radiation for anticancer therapy. Immunotherapy (2015) 0.84
Nivolumab for treating non-small cell lung cancer. Expert Opin Biol Ther (2015) 0.82
Analysis of the Abscopal Effect With Anti-PD1 Therapy in Patients With Metastatic Solid Tumors. J Immunother (2016) 0.79
A retrospective study of the novel combination of paclitaxel and S1 for pretreated advanced non-small cell lung cancer. Chemotherapy (2013) 0.78
Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet (2017) 2.22
Oncologic Outcomes of Segmentectomy Versus Lobectomy for Clinical T1a N0 M0 Non-Small Cell Lung Cancer. Ann Thorac Surg (2015) 0.98
Monitoring of treatment responses and clonal evolution of tumor cells by circulating tumor DNA of heterogeneous mutant EGFR genes in lung cancer. Lung Cancer (2016) 0.95
Dynamics of circulating tumor DNA represented by the activating and resistant mutations in epidermal growth factor receptor tyrosine kinase inhibitor treatment. Cancer Sci (2016) 0.89
Numerical indices based on circulating tumor DNA for the evaluation of therapeutic response and disease progression in lung cancer patients. Sci Rep (2016) 0.82
Early responses of EGFR circulating tumor DNA to EGFR tyrosine kinase inhibitors in lung cancer treatment. Oncotarget (2016) 0.78
Quality of life and survival survey of cancer cachexia in advanced non-small cell lung cancer patients-Japan nutrition and QOL survey in patients with advanced non-small cell lung cancer study. Support Care Cancer (2016) 0.77
Effectiveness of Tyrosine Kinase Inhibitors in Japanese Patients with Non-small Cell Lung Cancer Harboring Minor Epidermal Growth Factor Receptor Mutations: Results from a Multicenter Retrospective Study (HANSHIN Oncology Group 0212). Anticancer Res (2015) 0.77
Novel chemoradiotherapy with concomitant boost thoracic radiation and concurrent cisplatin and vinorelbine for stage IIIA and IIIB non-small-cell lung cancer. Clin Lung Cancer (2014) 0.76
Transient appearance of circulating tumor DNA associated with de novo treatment. Sci Rep (2016) 0.75
A long-term survivor of non-small-cell lung cancer harboring concomitant EGFR mutation and ALK translocation. Respir Med Case Rep (2016) 0.75